Cargando…

Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review

Leptomeningeal metastases (LM) are rare and catastrophic for metastatic breast cancer (MBC). The prognosis of HER2-positive breast cancer (BC) with LM is extremely poor. There is no high-quality evidence of treatment regimens in HER2-positive BC with LM yet. Here, we present a case of LM in a 50-yea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chi, Yajing, Shang, Mao, Xu, Liang, Gong, Heyi, Tao, Rongjie, Song, Lihua, Zhang, Baoxuan, Yin, Sha, Cong, Binbin, Li, Huihui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888838/ https://www.ncbi.nlm.nih.gov/pubmed/35251981 http://dx.doi.org/10.3389/fonc.2022.811919

Ejemplares similares

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Li, Yi, et al.
Publicado: (2021)

Efficacy and safety of pyrotinib‐containing regimen in the patients with HER2‐positive metastatic breast cancer: A multicenter real‐world study
por: Yin, Sha, et al.
Publicado: (2022)

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study
por: Xie, Yizhao, et al.
Publicado: (2021)

Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial
por: He, Maiyue, et al.
Publicado: (2023)

Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study
por: Liu, Chien-Ting, et al.
Publicado: (2021)

Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma
por: Qin, Rong-Sheng, et al.
Publicado: (2018)

Anti-tumor effects of low-dose metronomic vinorelbine in combination with alpelisib in breast cancer cells
por: Krajnak, Slavomir, et al.
Publicado: (2023)

Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
por: Yan, Min, et al.
Publicado: (2023)

Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report
por: Huang, Le-Tian, et al.
Publicado: (2019)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
por: Adamo, Barbara, et al.
Publicado: (2019)

Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial
por: Wang, Zijing, et al.
Publicado: (2021)

Neoadjuvant pyrotinib plus trastuzumab and vinorelbine for HER2-positive locally advanced breast cancer patient who was initially resistant to HP therapy: a case report and literature review
por: Liu, Mei, et al.
Publicado: (2023)

Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib
por: Lian, Xiangyao, et al.
Publicado: (2020)

Pyrotinib as a therapeutic for HER2-positive breast cancer
por: Kioutchoukova, Ivelina, et al.
Publicado: (2023)

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
por: Alder, Laura, et al.
Publicado: (2023)

Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells
por: Biziota, Eirini, et al.
Publicado: (2016)

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer
por: Chai, Yue, et al.
Publicado: (2023)

The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
por: Wang, Xinwei, et al.
Publicado: (2022)

Durable effect of pyrotinib plus capecitabine in HER-2+ breast cancer patient undergoing peritoneal dialysis: A case report and literature review
por: Jin, Xiangting, et al.
Publicado: (2022)

An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer
por: Pujol, Jean-Louis, et al.
Publicado: (2019)

Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience
por: Rossi, David
Publicado: (2020)

P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer
por: Chen, Hao, et al.
Publicado: (2023)

Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer
por: Li, Yan, et al.
Publicado: (2022)

Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
por: Al-Sukhun, Sana, et al.
Publicado: (2023)

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
por: Pepe, F. F., et al.
Publicado: (2022)

Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine – a Phase I trial
por: Guetz, Sylvia, et al.
Publicado: (2017)

Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis
por: Mao, Xiaoyun, et al.
Publicado: (2022)

Pyrotinib enhances the radiosensitivity of HER2-overexpressing gastric and breast cancer cells
por: Huang, Tingting, et al.
Publicado: (2020)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
por: Wang, Chaokun, et al.
Publicado: (2021)

Efficacy and safety of pyrotinib and radiotherapy vs. pyrotinib-based therapy in patients with HER2(+) breast cancer with brain metastasis: a retrospective cohort study
por: Chen, Jiaxin, et al.
Publicado: (2022)

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
por: Ma, Xiaoping, et al.
Publicado: (2022)

Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
por: Qi, Xiaowei, et al.
Publicado: (2023)

The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study
por: Li, Fu, et al.
Publicado: (2023)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis
por: Gebbia, Vittorio, et al.
Publicado: (2020)

Durable clinical benefit of letrozole in leptomeningeal metastasis of breast cancer
por: Takanashi, Toshihiro, et al.
Publicado: (2019)

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study
por: Cazzaniga, M. E., et al.
Publicado: (2016)

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
por: Guan, Xiuwen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_emc87os0t6f89na5vdvqn6jv9i